Evidence map›Paper›PMID 25880088›Full record

ArticleCell death & disease2015

BCL-2 is dispensable for thrombopoiesis and platelet survival.

M A Debrincat, I Pleines, M Lebois, R M Lane, M L Holmes, J Corbin, C J Vandenberg, W S Alexander, A P Ng, A Strasser and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death & disease, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 86 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Targeting BCL-xL in Myeloid Malignancies: From Inhibitors to PROTAC.Journal of cellular and molecular medicine · 2026
    Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Cadherin-11 targeted cell-specific liposomes enabled skin fibrosis treatment by inducing apoptosis.Journal of controlled release : official journal of the Controlled Release Society · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

M A Debrincat1] The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, VIC, Australia [2] Department of Medical Biology, The University of Melbourne, 1G Royal Parade, Parkville, VIC, Australia.
I Pleines1] The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, VIC, Australia [2] Department of Medical Biology, The University of Melbourne, 1G Royal Parade, Parkville, VIC, Australia.
M LeboisThe Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, VIC, Australia.
R M LaneThe Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, VIC, Australia.
M L HolmesThe Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, VIC, Australia.
J CorbinThe Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, VIC, Australia.
C J Vandenberg1] The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, VIC, Australia [2] Department of Medical Biology, The University of Melbourne, 1G Royal Parade, Parkville, VIC, Australia.
W S Alexander1] The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, VIC, Australia [2] Department of Medical Biology, The University of Melbourne, 1G Royal Parade, Parkville, VIC, Australia.
A P Ng1] The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, VIC, Australia [2] Department of Medical Biology, The University of Melbourne, 1G Royal Parade, Parkville, VIC, Australia.
A Strasser1] The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, VIC, Australia [2] Department of Medical Biology, The University of Melbourne, 1G Royal Parade, Parkville, VIC, Australia.
P Bouillet1] The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, VIC, Australia [2] Department of Medical Biology, The University of Melbourne, 1G Royal Parade, Parkville, VIC, Australia.
M Sola-VisnerBoston Children's Hospital, Division of Newborn Medicine, Boston, MA, USA.
B T Kile1] The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, VIC, Australia [2] Department of Medical Biology, The University of Melbourne, 1G Royal Parade, Parkville, VIC, Australia.
E C Josefsson1] The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, VIC, Australia [2] Department of Medical Biology, The University of Melbourne, 1G Royal Parade, Parkville, VIC, Australia.
Walter and Eliza Hall Institute of Medical Research · AUUniversity of Melbourne · AUBoston Children's Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Navitoclax (ABT-263), an inhibitor of the pro-survival BCL-2 family proteins BCL-2, BCL-XL and BCL-W, has shown clinical efficacy in certain BCL-2-dependent haematological cancers, but causes dose-limiting thrombocytopaenia. The latter effect is caused by Navitoclax directly inducing the apoptotic death of platelets, which are dependent on BCL-XL for survival. Recently, ABT-199, a selective BCL-2 antagonist, was developed. It has shown promising anti-leukaemia activity in patients whilst sparing platelets, suggesting that the megakaryocyte lineage does not require BCL-2. In order to elucidate the role of BCL-2 in megakaryocyte and platelet survival, we generated mice with a lineage-specific deletion of Bcl2, alone or in combination with loss of Mcl1 or Bclx. Platelet production and platelet survival were analysed. Additionally, we made use of BH3 mimetics that selectively inhibit BCL-2 or BCL-XL. We show that the deletion of BCL-2, on its own or in concert with MCL-1, does not affect platelet production or platelet lifespan. Thrombocytopaenia in Bclx-deficient mice was not affected by additional genetic loss or pharmacological inhibition of BCL-2. Thus, BCL-2 is dispensable for thrombopoiesis and platelet survival in mice.

Indexed as

Animalsbcl-X ProteinBlood PlateletsCell SurvivalMiceMice, TransgenicProto-Oncogene Proteins c-bcl-2ThrombocytopeniaThrombopoiesisBcl2l1 protein, mouseBcl2 protein, mousebcl-X ProteinProto-Oncogene Proteins c-bcl-2

Identifiers

PMID25880088
PMCPMC4650559
OpenAlexW2001699624

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.